T-Cell Depletion Studies Should Include Acute GVHD As Endpoint - FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Clinical trials of T-cell depletion (TCD) devices for bone marrow transplant procedures should have as their target endpoints the decreased incidence of acute Graft Versus Host Disease (aGVHD) and a reduction in the number of T-cells in a graft, FDA's Biological Response Modifiers Advisory Committee recommended Nov. 13.